Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; its reference list is not available.

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Open access

Abstract

Background: Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta(1-42/1-40), glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) to identify cerebral amyloidosis and/or disease severity. Methods: We included individuals with a positive (n = 176: 63 ± 7 years, 87 (49%) females) or negative (n = 76: 61 ± 9 years, 27 (36%) females) amyloid PET status, with syndrome diagnosis subjective cognitive decline (18 PET+, 25 PET−), mild cognitive impairment (26 PET+, 24 PET−), or AD-dementia (132 PET+). Plasma Abeta(1-42/1-40), GFAP, and NfL were measured by Simoa. We applied two-way ANOVA adjusted for age and sex to investigate the associations of the plasma markers with amyloid PET status and syndrome diagnosis; logistic regression analysis with Wald’s backward selection to identify an optimal panel that identifies amyloid PET positivity; age, sex, and education-adjusted linear regression analysis to investigate associations between the plasma markers and neuropsychological test performance; and Spearman’s correlation analysis to investigate associations between the plasma markers and medial temporal lobe atrophy (MTA). Results: Abeta(1-42/1-40) and GFAP independently associated with amyloid PET status (p = 0.009 and p < 0.001 respectively), and GFAP and NfL independently associated with syndrome diagnosis (p = 0.001 and p = 0.048 respectively). The optimal panel identifying a positive amyloid status included Abeta(1-42/1-40) and GFAP, alongside age and APOE (AUC = 88% (95% CI 83–93%), 82% sensitivity, 86% specificity), while excluding NfL and sex. GFAP and NfL robustly associated with cognitive performance on global cognition and all major cognitive domains (GFAP: range standardized β (sβ) = − 0.40 to − 0.26; NfL: range sβ = − 0.35 to − 0.18; all: p < 0.002), whereas Abeta(1-42/1-40) associated with global cognition, memory, attention, and executive functioning (range sβ = 0.22 – 0.11; all: p < 0.05) but not language. GFAP and NfL showed moderate positive correlations with MTA (both: Spearman’s rho> 0.33, p < 0.001). Abeta(1-42/1-40) showed a moderate negative correlation with MTA (Spearman’s rho = − 0.24, p = 0.001). Discussion and conclusions: Combination of plasma Abeta(1-42/1-40) and GFAP provides a valuable tool for the identification of amyloid PET status. Furthermore, plasma GFAP and NfL associate with various disease severity measures suggesting potential for disease monitoring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-020-00682-7

Cites

Statistics

Figures

Fig. 1 Boxplots of raw plasma biomarker levels for amyloid PET negative (−) and amyloid PET positive (+) individuals. Statistical analysis was conducted using age and sex adjusted two-way ANOVAs for amyloid PET status and syndrome diagnosis on the plasma biomarker levels, of which the p value of the independent effect of PET status is presented. Plasma GFAP and plasma NfL, levels were natural log transformed prior to statistical analysis. Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; PET, positron emission tomography
Fig. 1 Boxplots of raw plasma biomarker levels for amyloid PET negative (−) and amyloid PET positive (+) individuals. Statistical analysis was conducted using age and sex adjusted two-way ANOVAs for amyloid PET status and syndrome diagnosis on the plasma biomarker levels, of which the p value of the independent effect of PET status is presented. Plasma GFAP and plasma NfL, levels were natural log transformed prior to statistical analysis. Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; PET, positron emission tomographyCC BY · PubMed Central
Fig. 2 Boxplots of raw plasma biomarker levels for amyloid PET status (negative: -; positive: +) in function of the syndrome diagnostic groups. Statistical analysis was conducted using age and sex adjusted two-way ANOVAs evaluating the independent effects of amyloid PET status and syndrome diagnosis on the plasma biomarker levels. For plasma Abeta(1-42/1-40), PET status had a main effect (p = 0009) but not syndrome diagnosis (p = 0.192). For GFAP, both PET (p < 0.001) and syndrome diagnosis (p = 0.048) had main effects. For NfL, syndrome diagnosis (p = 0.001) but not PET status (p = 0.155) had a main effect. Plasma GFAP and plasma NfL levels were natural log transformed prior to ANOVA. Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; PET, positron emission tomography
Fig. 2 Boxplots of raw plasma biomarker levels for amyloid PET status (negative: -; positive: +) in function of the syndrome diagnostic groups. Statistical analysis was conducted using age and sex adjusted two-way ANOVAs evaluating the independent effects of amyloid PET status and syndrome diagnosis on the plasma biomarker levels. For plasma Abeta(1-42/1-40), PET status had a main effect (p = 0009) but not syndrome diagnosis (p = 0.192). For GFAP, both PET (p < 0.001) and syndrome diagnosis (p = 0.048) had main effects. For NfL, syndrome diagnosis (p = 0.001) but not PET status (p = 0.155) had a main effect. Plasma GFAP and plasma NfL levels were natural log transformed prior to ANOVA. Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; PET, positron emission tomographyCC BY · PubMed Central
Fig. 3 ROCs for amyloid PET positivity in the total study population (a) and non-demented subset (b). Individual plasma biomarkers GFAP, Abeta(1-42/1-40), and NfL are plotted as well as the combined panel best predicting amyloid PET positivity. Panel in the total population (a) are the predicted values of the combined plasma Abeta(1-42/1-40), plasma GFAP, age, and APOE ε4 carriership panel (AUC = 0.88 (95% CI 0.83–0.93)). Panel in the non-demented population (SCD + MCI) (b) are the predicted values of the combined plasma Abeta(1-42/1-40), plasma GFAP, and APOE ε4 carriership panel (AUC = 0.84 (95% CI 0.76–0.92)). GFAP, glial fibrillary acidic protein; Abeta, amyloid beta; NfL, neurofilament light
Fig. 3 ROCs for amyloid PET positivity in the total study population (a) and non-demented subset (b). Individual plasma biomarkers GFAP, Abeta(1-42/1-40), and NfL are plotted as well as the combined panel best predicting amyloid PET positivity. Panel in the total population (a) are the predicted values of the combined plasma Abeta(1-42/1-40), plasma GFAP, age, and APOE ε4 carriership panel (AUC = 0.88 (95% CI 0.83–0.93)). Panel in the non-demented population (SCD + MCI) (b) are the predicted values of the combined plasma Abeta(1-42/1-40), plasma GFAP, and APOE ε4 carriership panel (AUC = 0.84 (95% CI 0.76–0.92)). GFAP, glial fibrillary acidic protein; Abeta, amyloid beta; NfL, neurofilament lightCC BY · PubMed Central
Fig. 4 Heat plots with predicted probabilities for amyloid PET positivity in the total study population. Heat plots were constructed by filling out the logistic regression formula with constant = 0.839, and beta’s B = − 19.02 for Abeta(1-42/1-40), B = 0.019 for GFAP, B = − 0.618 for age (dichotomous variable: younger (= 0) versus older (= 1) than cohort’s average age of 63 years) and B = 1.625 for APOE ε4 carriership (non-carrier = 0, carrier = 1). Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; APOE, apolipoprotein E
Fig. 4 Heat plots with predicted probabilities for amyloid PET positivity in the total study population. Heat plots were constructed by filling out the logistic regression formula with constant = 0.839, and beta’s B = − 19.02 for Abeta(1-42/1-40), B = 0.019 for GFAP, B = − 0.618 for age (dichotomous variable: younger (= 0) versus older (= 1) than cohort’s average age of 63 years) and B = 1.625 for APOE ε4 carriership (non-carrier = 0, carrier = 1). Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; APOE, apolipoprotein ECC BY · PubMed Central
Fig. 5 Associations of plasma biomarkers with cognitive performance across the total study cohort, presented as standardized effect sizes with 95% confidence intervals of age, sex, and education (according to Verhage (1965) system) adjusted linear regression analysis between plasma biomarker levels and cognitive domain scores. Plasma Abeta(1-42/1-40) levels were inverted prior to analysis, so that the direction of effect sizes are comparable for all markers. Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; NfL, neurofilament light
Fig. 5 Associations of plasma biomarkers with cognitive performance across the total study cohort, presented as standardized effect sizes with 95% confidence intervals of age, sex, and education (according to Verhage (1965) system) adjusted linear regression analysis between plasma biomarker levels and cognitive domain scores. Plasma Abeta(1-42/1-40) levels were inverted prior to analysis, so that the direction of effect sizes are comparable for all markers. Abeta, amyloid beta; GFAP, glial fibrillary acidic protein; NfL, neurofilament lightCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 60 · Cited by 258

Metadata

Authors
Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., van Berckel, B. N. M., Scheltens, P., van der Flier, W. M., Stoops, E., Vanderstichele, H. M., & Teunissen, C. E.
Affiliations
  • Amsterdam Neuroscience (NL)
  • ADx NeuroSciences (BE)
  • Lund University (SE)
Corresponding author
Verberk, Inge M. W.
Venue
Alzheimer's Research & Therapy
Published
2020-09-28
Volume
12
Issue
1
Pages
118-118
ISSN
1758-9193 (ISSN-L)
OpenAlex
W3088634533
Cited by
258
References
60
Citations by year
2026: 28 · 2025: 36 · 2024: 53 · 2023: 45 · 2022: 54 · 2021: 40 · 2020: 2
FWCI
25.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Alzheimer Nederland (NL-17004)
  • Health˜Holland (LSHl17OO1)
  • NCDC, Deltaplan Dementie, ZonMW Memorabel (73305095005)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, cerebral amyloidosis, glial fibrillary acidic protein, neurofilament light chain, plasma biomarkers, amyloid PET, blood-based biomarkers, subjective cognitive decline, mild cognitive impairment, Alzheimer's dementia, cognitive performance, medial temporal lobe atrophy, apolipoprotein E, biomarker panel
MeSH terms
Alzheimer Disease, Amyloidosis, Female, Glial Fibrillary Acidic Protein, Humans, Intermediate Filaments, Biomarkers, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. https://app.cochat.ai/papers/10.1186/s13195-020-00682-7
The paper
Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., van Berckel, B. N. M., Scheltens, P., van der Flier, W. M., Stoops, E., Vanderstichele, H. M., & Teunissen, C. E. (2020). Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00682-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.